Heartflow Inc. upped the price of shares in its IPO for a second time to $19 on Aug. 7 before opening on the Nasdaq as “HTFL” ...

Quantumpharm Inc., known as Xtalpi Inc., announced receiving $51 million up front from a potential $5.99 billion deal with ...

Minghui Pharmaceutical Ltd. announced it is raising $131 million in a pre-IPO financing round Aug. 7. The funds will be used to advance its cancer and inflammatory disease pipeline, which include a PD ...

The difference between the origin of Alzheimer's disease (AD) and its symptoms is an obstacle to finding effective treatments. Scientists focused on amyloid-β (Aβ) plaques and tau aggregates to slow ...

The U.S. Federal Trade Commission (FTC) reported Aug. 6 that it will try to block Edwards Lifesciences Corp.’s proposed ...

A federal appeals court opened the door Aug. 6 for an amended class-action lawsuit alleging that Astrazeneca plc, Eli Lilly ...

Location, location, location. While location is as important in manufacturing as it is in buying a home, it could become even ...

A management-led syndicate of prominent investors acquired a majority stake in Histosonics Inc. that values the company at ...

With half-year industry financings down 59% from last year, and a U.S. administration supportive of cryptocurrencies, ...

Infectious disease biopharma stocks bounced back in June and July, with the BioWorld Infectious Disease Index (BIDI) closing July up 4.34%. This marked a sharp reversal from earlier in the year, as ...

Pharmaceutical Technology Co. Ltd., Quanzhou Haichuang Pharmaceutical Technology Co. Ltd. and Suzhou Grandkol Pharm Technology Co. Ltd. have discovered new compounds.

Hefei Institutes of Physical Science Chinese Academy of Sciences has synthesized phosphoglycerate kinase 1 (PGK1) inhibitors reported to be useful for the treatment of inflammatory bowel disease.